融资概述 - Hofseth Biocare ASA（HBC）已完成一次私募配售，并宣布将进行后续发行，后续发行最多可筹集总收益约3000万挪威克朗 [2][3] - 后续发行将提供最多16,666,666股新股，每股发行价与私募配售的认购价相同 [2] 发行细节 - 合格股东将根据其在记录日持有的每股现有股份获得0.1134份不可转让的认购权，每份认购权有权认购一股发行股份 [4] - 如果后续发行的认购期内未能全部认购发行股份（包括超额认购），剩余股份可由私募配售中的投资者或董事会认为对公司具有战略重要性的其他投资者认购 [3] - 认购期从2025年11月10日09:00（CET）开始，至2025年11月20日16:30（CET）结束，未使用的认购权在到期后将失效 [5] 时间表与条件 - 支付发行股款的预计到期日为2025年11月26日，发行股份预计在2025年12月2日左右在奥斯陆证券交易所上市交易 [6] - 后续发行的完成取决于多项条件，包括公司股东大会（将于2025年11月20日举行）通过相关决议、至少1股发行股份被认购、收到认购款项以及完成工商注册等 [7] - 本次发行的法律顾问为Advokatfirmaet CLP DA [8]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Frøya, 2 September 2025: Reference is made to the stock exchange announcement by Kaldvik AS (“Kaldvik” or the “Company”) on 29 August 2025 regarding the board of directors' reso ...

文章核心观点 公司完成私募配售，董事会将考虑对特定股东进行后续发售，后续发售存在不确定性，取决于公司股价等因素，同时介绍了发售相关信息及参与方情况 [2][3][4] 后续发售相关信息 - 条款公布日期为2025年6月5日 [3] - 含认购权最后一天为2025年6月4日 [3] - 不含认购权第一天为2025年6月5日 [3] - 登记日期为2025年6月6日 [3] - 预计批准日期为2025年6月19日左右 [3] - 最多发行430万股新股 [3] - 认购价格为每股14挪威克朗 [3] - 认购权不上市交易 [3] - 发售需满足私募配售完成、相关公司决议及国家招股说明书登记等条件 [3] - 符合条件股东有按比例认购权，不允许超额认购，认购权不可交易 [3] 发售不确定性 - 后续发售是否进行取决于公司股价发展，公司有权自行决定不进行或取消发售 [4] 参与方情况 - DNB Carnegie担任独家全球协调人和联合账簿管理人，Arion Banki hf和Nordea Bank Abp担任联合账簿管理人 [5] - Advokatfirmaet Thommessen AS担任公司法律顾问 [5] 目标市场 - 私募配售目标市场为非专业、专业及合格对手方，需具备对资本市场的基本了解、能承受投资损失、愿意接受风险及考虑股票流动性的投资期限 [15] - 负面目标市场为寻求全额资本保护、无风险承受能力、需要全额保证收入或完全可预测回报的客户 [16] - 经理仅允许向符合欧盟制造商目标市场评估要求的投资者，以及北欧以外至少可归类为专业客户或合格对手方的投资者分销 [17] - 向欧盟以外投资者分销需满足经理可接触、能提供充分确认及满足制造商目标市场评估最低要求 [18]

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Frøya, 4 June 2025: Reference is made to the stock exchange release including the Q1 report and presentation published by Kaldvík AS (the "Company") on 28 May 2025 with details about the Company's refinancing package. As stated therein, the Company has received confirmatio ...